Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 91

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 91
---
 business and successfully execute our business plan.

Additionally, all of our
officers and directors, in the course of their other business activities, may become aware of investments, business opportunities, or
information which may be appropriate for presentation to us as well as to other entities to which they owe a fiduciary duty. They may
also in the future become affiliated with entities that are engaged in business or other activities similar to those we intend to conduct.
As a result, they may have conflicts of interest in determining to which entity particular opportunities or information should be presented.
If, as a result of such conflict, we are deprived of investment, business or information, the execution of our business plan and our
ability to effectively compete in the marketplace may be adversely affected.

<div align='center'>55

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus contains
forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives
and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements
of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our clinical                                                                             
 trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of                                                                                      
 our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market                                                                                                           
 opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we 
 are targeting;                                                                                                                   |

| ● | our ability to accurately                                                          
 identify demand for our Gelrin hydrogel platform or any future product candidates; |

| ● | the success of competing                    
 therapies that are or may become available; |